Have a question?
Please get in touch with our team in case of any queries
THE U.S. COMPOUNDING PHARMACIES MARKET SIZE IS EXPECTED TO REACH USD 6.21 BILLION BY 2029 FROM USD 4.89 BILLION IN 2023, GROWING AT A CAGR OF 4.06% DURING THE FORECAST PERIOD.
The U.S. Compounding Pharmacies Market Size, Share, & Trends Analysis Report By
- Product Type: Oral, Topical, Parenteral, Ophthalmic, and Others
- Pharmacy Type: 503A and 503B
- Sterility Type: Sterile and Non-sterile
- Compounding Type: Pharmaceutical Ingredient Alteration (PIA), Currently Unavailable Pharmaceutical Manufacturing (CUPM), and Pharmaceutical Dosage Alteration (PDA)
- Application: Pain Management, Hormone Replacement Therapy, Anti-aging & Skin Care, Nutritional Supplements, and Others
- Age Cohort: Adult, Geriatric, and Pediatric
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2024–2029.
This report includes market data points, ranging from trend
analyses to market estimates & forecasts that you can customize
U.S. COMPOUNDING PHARMACIES MARKET REPORT SCOPE
REPORT ATTRIBUTE | DETAILS |
---|---|
Market Size (2029) | USD 6.21 Billion |
Market Size (2023) | USD 4.89 Billion |
CAGR (2023-2029) | 4.06% |
HISTORIC YEAR | 2020-2022 |
BASE YEAR | 2023 |
FORECAST YEAR | 2024-2029 |
SEGMENTS BY | Product Type, Pharmacy Type, Sterility Type, Compounding Type, Application, Age Cohort |
KEY PLAYERS | Avella Specialty Pharmacy, CAPS, Fagron, Fresenius Kabi, and PenCol Pharmacy |
INDUSTRY OUTLOOK
The U.S. compounding pharmacies market size was valued at USD 4.89 billion in 2023 and is expected to reach USD 6.21 billion by 2029, growing at a CAGR of 4.06% during the forecast period. The demand for customized drug formulations grows as healthcare increasingly moves towards personalized medicine. The market provides a solution for patients who require specific dosages, alternative delivery methods, or medications free from certain allergens or additives. Compounded medications can address gaps left by commercial drug manufacturers, such as discontinued drugs or those unavailable in specific strengths or forms. This capability is crucial for patients who rely on medications that are otherwise unavailable.
The U.S. compounding pharmacies market occupies a unique niche within the broader healthcare landscape, providing customized medications that cater to the specific needs of individual patients. Unlike conventional pharmaceuticals, which are produced in bulk by large pharmaceutical companies, licensed pharmacists prepare compounded drugs according to specific prescriptions. This market segment plays a vital role in offering personalized treatment solutions, addressing gaps in conventional drug availability, and meeting the needs of patients requiring unique formulations.
A complex interplay between federal and state authorities characterizes the regulatory framework for compounding pharmacies in the US. Historically, compounding practices were subject to oversight primarily by state boards of pharmacy. However, high-profile cases of contamination and quality issues have prompted increased federal scrutiny. The Drug Quality and Security Act (DQSA) of 2013 introduced new regulations, particularly focusing on "outsourcing facilities" that compound drugs in bulk for interstate distribution. This act aims to enhance the safety and quality of compounded drugs by imposing stricter guidelines and registration requirements. Furthermore, the U.S. compounding pharmacies market plays a crucial role in providing personalized medication solutions and addressing specific patient needs that are not met by standard pharmaceutical products. Driven by factors such as the demand for personalized medicine, an aging population, and technological advancements, the market continues to evolve.
MARKET TRENDS & DRIVERS
Advanced Technology Integration
Integrating advanced technologies such as automation, robotic systems, and digital platforms creates new opportunities for the U.S. compounding pharmacies market. These innovations improve operational efficiency, enhance patient care, ensure compliance, and pave the way for future advancements in personalized medicine. As pharmacies continue to adopt these technologies, they will be better equipped to meet the evolving demands of healthcare and provide tailored medication solutions to patients. Also, adopting artificial intelligence (AI) and machine learning (ML) holds great potential for predictive analytics in compounding, such as anticipating patient needs and personalizing formulations based on genetic profiles.
Growing Demand for Compounded Bioidentical Menopausal Hormone Therapy (BMHT) Among Women
The growing demand for compounded bio-identical menopausal hormone therapy is reshaping the U.S. compounding pharmacies market, providing new opportunities for growth and innovation. As women increasingly seek personalized, natural solutions for managing menopausal symptoms, compounding pharmacies are well-positioned to meet this demand. By offering customized hormone treatments that prioritize patient safety and wellness, compounding pharmacies can capitalize on the expanding market for BMHT while contributing to the broader trend of personalized healthcare in the US.
Growing Geriatric Population & Acceptance of Personalized Medications
The growing geriatric population and the increasing acceptance of personalized medications are key drivers of the U.S. compounding pharmacies market. Compounding pharmacies are uniquely positioned to meet the complex and individualized needs of elderly patients, providing customized solutions that enhance healthcare outcomes. As demand for tailored medications grows, compounding pharmacies will continue to play a vital role in the U.S. healthcare system, providing personalized care for diverse patients.
Growing Significance of Compounding for Drug Adherence
The growing significance of compounding for drug adherence is a key driver of the U.S. compounding pharmacies market. Compounding pharmacies play a vital role in improving medication compliance and, ultimately, patient outcomes by offering customized solutions that address the specific needs of diverse patient populations. With advancements in technology and a growing focus on personalized medicine, the future of the compounding pharmacies market is poised for continued growth and innovation.
Rapid Identification of Chronic Diseases
The increasing prevalence of chronic diseases and the advancements in their rapid identification are reshaping the U.S. compounding pharmacies market. Compounding pharmacies offer customized treatment options that address the specific needs of patients with chronic conditions, improving medication adherence, patient outcomes, and overall quality of care. As the demand for personalized medicine continues to grow, compounding pharmacies will remain at the forefront of providing innovative and tailored solutions for chronic disease management, driving their expansion and influence within the healthcare sector.
SEGMENTATION INSIGHTS
INSIGHTS BY PRODUCT TYPE
The U.S. compounding pharmacies market by product type is segmented into oral, topical, parenteral, ophthalmic, and others. The oral segment holds the most significant U.S. market share. The oral compounds segment can be tailored to patients with allergies to certain excipients or those who require specific dosages that are not commercially available. Customized oral medications are particularly beneficial for pediatric and geriatric patients needing adjusted dosages or specific formulations to improve adherence. Compounding pharmacies can add flavorings to oral medications to make them more palatable for children or patients with difficulty swallowing pills. The demand for oral compounds is driven by the need for personalized dosing, especially in conditions like hormone replacement therapy (HRT) and pain management. Furthermore, parenteral compounds are often used for patients needing customized dosages or drug combinations unavailable in commercial products. Many compounded parenteral medications are utilized in hospital settings for specialized treatments, such as chemotherapy or pain management, where individualized care is crucial.
INSIGHTS BY PHARMACY TYPE
The 503A pharmacy type held the most significant share of the U.S. compounding pharmacies market and is projected to witness the highest segmental CAGR of 4.30% during the forecast period. 503A pharmacies are traditional compounding pharmacies that primarily focus on preparing medications for individual patients based on a prescription from a licensed healthcare provider. They often serve local communities and focus on providing customized solutions for conditions such as hormone replacement therapy, pediatric needs, and dermatological treatments. State boards of pharmacy primarily regulate 503A pharmacies and must adhere to state-specific compounding regulations. The FDA's oversight is more limited compared to 503B facilities. Furthermore, the 503B pharmacies, also known as outsourcing facilities, are designed to compound medications on a larger scale, primarily for healthcare institutions such as hospitals, clinics, and long-term care facilities. 503
INSIGHTS BY STERILITY TYPE
The U.S. compounding pharmacies market by sterility type is segmented into sterile and non-sterile. The sterile segment holds the largest segmental market share. The demand for sterile compounding is driven by its applications in hospitals and clinical settings, where compounded sterile preparations (CSPs) are used for various treatments. These include intravenous (IV) medications, chemotherapy agents, and other critical therapies. The growth of personalized medicine and an increasing number of patients requiring complex treatments contribute to the rising demand for sterile compounding services. Furthermore, the demand for non-sterile compounding is significant due to its broad range of applications. This includes customized formulations for hormone replacement therapy, pediatric medications, and dermatological treatments.
INSIGHTS BY COMPOUNDING TYPE
The U.S. compounding pharmacies market by compounding type is segmented into pharmaceutical ingredient alteration (PIA), currently unavailable pharmaceutical manufacturing (CUPM), and pharmaceutical dosage alteration (PDA). The pharmaceutical ingredient alteration (PIA) segment dominated the U.S. market share, accounting for over 39% of the revenue in 2023. PIA involves modifying the ingredients of a medication to meet the specific needs of individual patients better. PIA allows for significant customization, addressing patients requiring non-standard dosages or formulations due to unique health conditions, allergies, or other requirements. The demand for PIA is driven by patients needing tailored solutions for conditions that standard pharmaceutical formulations cannot adequately address. This includes pediatric patients who may need medications in different dosages or forms. Furthermore, the CUPM segment is critical in filling gaps caused by drug shortages or discontinuations. This ensures patients can continue receiving necessary treatments even when standard options are unavailable. CUPM is particularly important for patients requiring niche or rare medications that mainstream pharmaceutical manufacturers do not produce. This can include specialized cancer treatments or rare disease medications.
INSIGHTS BY APPLICATION
The U.S. compounding pharmacies market by application is segmented into pain management, hormone replacement therapy, anti-aging & skin care, nutritional supplements, and others. The pain management segment holds the most substantial market share. Compounding pharmacies play a crucial role in pain management by offering customized medications tailored to patients' needs. For chronic pain sufferers, commercially available pain relief drugs may not be effective or may cause adverse side effects. Compounded pain medications allow for personalized dosages, alternative delivery methods (like topical creams, gels, or transdermal patches), and combinations of multiple drugs to maximize relief while minimizing side effects. The increasing opioid crisis has also spurred the demand for non-opioid, compounded alternatives to manage chronic pain, positioning compounding pharmacies as critical in pain management solutions. Furthermore, hormone replacement therapy (HRT) is one of the most sought-after services in the U.S. compounding pharmacies market. Many patients undergoing HRT for conditions like menopause, thyroid disorders, or low testosterone levels seek bioidentical hormones, which are chemically identical to the hormones naturally produced by the body. Compounding pharmacies offer customized formulations of bioidentical hormones in various forms—creams, gels, pills, or injections—adjusting dosages to meet individual needs. This market has experienced substantial growth due to the aging population and increased awareness of personalized medicine options for hormonal imbalances.
INSIGHTS BY AGE COHORT
The adult age cohort segment dominates the U.S. compounding pharmacies market share. Many adults seek personalized treatments for conditions requiring precise dosage adjustments or specific formulations unavailable through commercial medications. Common treatments include hormone replacement therapy (HRT) for both men and women, pain management, and dermatological compounds for skin conditions. Adults also benefit from compounded medications to avoid allergens or intolerances in standard pharmaceuticals and medications tailored to specific lifestyle needs. Furthermore, the pediatric population is a key demographic for the United States compounding pharmacies market, as children often require customized medications unavailable in standard dosages or formulations. Compounded medications are essential for:
- Adjusting the strength of medications to suit a child's weight or age
- Creating alternative dosage forms, such as flavored liquids, chewable tablets, or topical gels, to make administration easier for young children
- Removing allergens or non-essential ingredients that could cause adverse reactions in children
Pediatric patients frequently require compounded medications for conditions such as asthma, allergies, dermatological issues, and rare diseases, where commercially available drugs may not be appropriate or palatable. The ability to offer personalized, child-friendly medications enhances treatment adherence and improves overall patient outcomes in this age group.
COMPETITIVE LANDSCAPE
The U.S. compounding pharmacies market operates in a dynamic and evolving landscape characterized by diverse players, regulatory challenges, and increasing demand for personalized medications. As healthcare trends shift towards personalized treatment solutions, the competition in this sector has intensified. Compounding pharmacies, which offer customized medications tailored to individual patient needs, compete with large pharmaceutical manufacturers, retail pharmacies, and specialized compounding firms. This competition is shaped by factors such as regulatory compliance, quality assurance, technological advancements, and market differentiation. Furthermore, technology plays an increasingly important role in the US compounding pharmacies market. Pharmacies that invest in automation, digital platforms, and advanced compounding equipment have a competitive advantage. Automated compounding machines, for example, can enhance accuracy, reduce human error, and increase production efficiency, especially in sterile environments where precision is critical.
The key players in the U.S. compounding pharmacies market are Avella Specialty Pharmacy, CAPS, Fagron, Fresenius Kabi, and PenCol Pharmacy. Avella Specialty Pharmacy, a prominent player in the market, is known for its focus on providing personalized, high-quality compounded medications. Avella specializes in sterile and non-sterile compounding, offering a wide range of personalized medications, including hormone replacement therapies, pain management solutions, and dermatological preparations. Also, Avella invests in advanced compounding technologies and quality assurance practices to ensure the safety and efficacy of its products.
Frequently Asked Questions
How big is the U.S. compounding pharmacies market?
What is the growth rate of the U.S. compounding pharmacies market?
What are the significant trends in the U.S. compounding pharmacies market?
Which compounding type segment dominates the U.S. compounding pharmacies market share?
Who are the key players in the U.S. compounding pharmacies market?
The U.S. compounding pharmacies market size is expected to grow at a CAGR of approximately 4.06% from 2023 to 2029.
The following factors are likely to contribute to the growth of the U.S. compounding pharmacies market during the forecast period:
- Growing Geriatric Population & Acceptance of Personalized Medications
- Growing Significance of Compounding for Drug Adherence
- Increasing Drug Shortage
- Rapid Identification of Chronic Diseases
Base Year: 2023
Forecast Year: 2024-2029
The report considers the present scenario of the U.S. compounding pharmacies market and its market dynamics for 2024−2029. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes leading companies and several other prominent companies operating in the market.
Key Company Profiles
- Avella Specialty Pharmacy
- Business Overview
- Product Offerings
- Key Strategies
- Key Strengths
- Key Opportunities
- CAPS
- Fagron
- Fresenius Kabi
- PenCol Pharmacy
Other Prominent Vendors
- Austin Compounding Pharmacy
- Business Overview
- Product Offerings
- Capstone Compounding Pharmacy
- Charles River Laboratories
- Dougherty's Pharmacy
- Eastern States Compounding Pharmacy
- Everwell Specialty Pharmacy
- Harrow
- Hill’s Compounding Pharmacy and Milford Pharmacy
- INNOVATIVE RX
- Institutional Pharmacy Solutions
- ITC Compounding Pharmacy
- McGuff Company
- MediVera Compounding Pharmacy
- Nephron Pharmaceuticals
- PCCA
- Precision Compounding Pharmacy
- QuVa Pharma
- Sixth Avenue Medical Pharmacy
- St. Anthony Pharmacy
- The Compounding Pharmacy of America
- Triangle Compounding
- Valor Compounding Pharmacy
- Vertisis Custom Pharmacy
Segmentation by Product Type
- Oral
- Topical
- Parenteral
- Ophthalmic
- Others
Segmentation by Pharmacy Type
- 503A
- 503B
Segmentation by Sterility Type
- Sterile
- Non-sterile
Segmentation by Compounding Type
- Pharmaceutical Ingredient Alteration (PIA)
- Currently Unavailable Pharmaceutical Manufacturing (CUPM)
- Pharmaceutical Dosage Alteration (PDA)
Segmentation by Application
- Pain Management
- Hormone Replacement Therapy
- Anti-aging & Skin Care
- Nutritional Supplements
- Others
Segmentation by Age Cohort
- Adult
- Geriatric
- Pediatric
For more details, please reach us at enquiry@arizton.com
For more details, please reach us at enquiry@arizton.com
Select a license type that suits your business needs
Single User Licence
- Report accessible by one user only
- Free 10% or 3 days of customization
- Free post-sale service assistance
- Continuous support through email
5 User Licence
- Report accessible by 5 users within the organization
- Free 15% or 4.5 days of customization
- Continuous support through email and telephone
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
- Free Datasheet worth $1500
- Report accessible by the entire organization
- Free 20% or 6 days of customization
- Free post-sale service assistance
- Continuous support through email and telephone
- Direct access to lead analysts
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
- Report accessible by 1 user only
- Free 15% or 32 hours of customization
- Free post-sale service assistance
- Direct access to lead analysts
Frequently Asked Questions
How big is the U.S. compounding pharmacies market?
What is the growth rate of the U.S. compounding pharmacies market?
What are the significant trends in the U.S. compounding pharmacies market?
Which compounding type segment dominates the U.S. compounding pharmacies market share?
Who are the key players in the U.S. compounding pharmacies market?